AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of affected AZN investors. NEW YORK, July 9, 2026 /PRNewswire/ — AstraZeneca PLC (NYSE:…
Source: prnewswire
Country: United States